enGene

What enGene does

enGene is a clinical-stage biotechnology company developing detalimogene voraplasmid (formerly EG-70), a non-viral gene therapy for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company was founded in Canada in 2012 and became publicly traded on NASDAQ in November 2023 through a business combination with Forbion European Acquisition Corp.; it was renamed enGene Therapeutics Inc. in April 2026 to reflect its planned transition toward becoming a commercial organization. Its lead candidate is powered by the proprietary DDX (Dually Derivatized Oligochitosan) platform, a non-viral gene delivery technology that enables localized, intravesical administration of therapeutic genetic material designed to drive expression of immune-activating payloads (including IL-12 and double-stranded RNAs) directly at the bladder tumor site.

The company's clinical lead, detalimogene, is being studied in the LEGEND Phase 2 trial across multiple cohorts of NMIBC patients, including BCG-unresponsive, BCG-naïve, and BCG-exposed populations with or without carcinoma in situ, as well as BCG-unresponsive papillary-only disease. Pivotal Cohort 1 data showed a 54% complete response rate at any time (67/124 patients) and a 3.2% rate of progression to muscle-invasive or higher disease, with the FDA having granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations and selected detalimogene for the CMC Development and Readiness Pilot Program. The company positions detalimogene as an "off-the-shelf" intravesical therapy intended to fit into existing urology clinic workflows without specialized handling, cold-chain storage, urine bleaching, or extensive staff training.

enGene is currently pre-revenue with no commercial products. Its planned business model contemplates one-time-per-treatment pricing for detalimogene administered through urology practices and hospitals, supported by an enterprise field sales motion aimed at the approximately 17,000 addressable BCG-unresponsive NMIBC patients annually in the US. The company has funded operations through multiple capital transactions since its 2023 listing, including a $200M oversubscribed private placement in February 2024, a ~$130M public offering in November 2025, and a $125M expanded debt facility with Hercules Capital announced in January 2026. In June 2026, the company announced a 50% workforce reduction as a cash-conservation measure ahead of a critical regulatory readout and Biologics License Application submission targeted for the second half of 2026.

Name

enGene

Legal name

enGene Inc.

Website

https://engene.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

enGene is a clinical-stage biotechnology company developing detalimogene voraplasmid, a non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer, using its proprietary DDX platform. Pre-revenue, the company is targeting FDA approval and a 2027 commercial launch.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

akta.pro secondary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Gene therapy
• Bladder cancer treatment
• Non-viral delivery
• Biologic drug development
• Mucosal therapeutics

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Detalimogene Commercialization: enGene is a clinical-stage company developing detalimogene voraplasmid for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company plans to commercialize its gene therapy product following potential FDA approval, targeting urology practices and hospitals. Currently pre-revenue with no commercial products approved.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

enGene is a clinical-stage biopharmaceutical company developing detalimogene voraplasmid, an investigational non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapy is delivered intravesically using the company's proprietary DDX (Dually Derivatized Oligochitosan) platform, which enables localized delivery of genetic medicines to mucosal tissues such as the bladder. The company is preparing for potential FDA approval and commercial launch in 2027.

Product overview

enGene is a clinical-stage biotechnology company with a single-product focus developing detalimogene voraplasmid (EG-70), a non-viral gene therapy for non-muscle invasive bladder cancer. The therapy is powered by the proprietary DDX (Dually Derivatized Oligochitosan) platform technology, which enables localized delivery of genetic medicines to mucosal tissues. Detalimogene is currently in Phase 2 clinical trials (LEGEND study) across multiple patient cohorts and has received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company is preparing for potential FDA approval and commercial launch in 2027.

Differentiator

Problem solved

Functional benefit

Products and services

• Detalimogene Voraplasmid (EG-70) Investigational non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC) that delivers genetic instructions to bladder cells, enabling them to produce therapeutic proteins that activate local innate and adaptive immune responses against cancer. Designed for BCG-unresponsive patients with carcinoma in situ (CIS) and papillary-only NMIBC to delay or avoid radical cystectomy. Administered intravesically as an off-the-shelf therapy with no cold-chain storage requirement and one-hour dwell time.

Quantifiable outcome

• 54% complete response rate at any time in BCG-unresponsive NMIBC patients with CIS (67/124)
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor.

• Bladder Cancer Advocacy Network (BCAN)minorStrategic or Co-development PartnerenGene supports BCAN as part of its community investment initiatives, participating in patient advocacy activities including Walk to End Bladder Cancer to foster connection between employees and the company's mission.
• Life Science Cares BostonminorStrategic or Co-development PartnerenGene supports Life Science Cares Boston as a high-impact nonprofit organization, aligning with its commitment to community investment and corporate responsibility.
• Special Olympics MassachusettsminorStrategic or Co-development PartnerenGene participates in volunteer and fundraising opportunities including the Special Olympics Massachusetts BioBall event as part of its employee engagement and community support initiatives.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• CG Oncology: CG Oncology is developing CG0070, an oncolytic adenovirus-based intravesical therapy for BCG-unresponsive NMIBC. It is the closest late-stage head-to-head competitor to detalimogene, targeting the same indication with a different but also intravesical mechanism.
• UroGen Pharma: UroGen Pharma is developing UGN-102 (mitomycin) for NMIBC and has an established urology commercial footprint with Jelmyto. It is a direct intravesical-NMIBC competitor with a broader urology commercial platform.
• Merck & Co. Merck's Keytruda (pembrolizumab) received FDA approval in 2020 for BCG-unresponsive NMIBC. It is an established approved competing therapy in the same BCG-unresponsive NMIBC segment that detalimogene targets.
• ImmunityBio: ImmunityBio's Anktiva (N-803, nogapendekin alfa inbakicept-pmln) was FDA-approved in 2024 for BCG-unresponsive NMIBC with CIS. It is a directly competing approved therapy in enGene's lead indication.
• Ferring Pharmaceuticals: Ferring, partnered with Astellas, markets Adstiladrin (nadofaragene firadenovec), an intravesical gene therapy approved in late 2024 for BCG-unresponsive NMIBC. This is an approved gene-therapy competitor to detalimogene in the same setting.

Broad incumbents

• Astellas Pharma: Astellas co-markets Ferring's Adstiladrin in the U.S. for BCG-unresponsive NMIBC. As a large global urology/oncology incumbent with gene-therapy commercialization experience, it is a broader peer and potential BD partner for enGene.
• Johnson & Johnson: Johnson & Johnson's Balversa (erdafitinib) is approved for FGFR-altered urothelial carcinoma, giving it a presence in advanced bladder cancer. J&J is a broad incumbent in urologic oncology with the resources to compete with or acquire late-stage NMIBC assets.
• uniQure: uniQure is an established gene therapy company with AAV-based products approved or in late-stage trials for CNS, cardiovascular, and metabolic diseases. It is a broader incumbent peer operating in the gene therapy modality space.

Emerging players

• Kintor Pharmaceutical: Kintor is developing therapies for urologic cancers including NMIBC and prostate cancer. It is an emerging peer in the same urologic oncology space with partial clinical-stage overlap.
• MeiraGTx: MeiraGTx is a clinical-stage gene therapy company with proprietary viral and non-viral delivery platforms for ocular, CNS, and metabolic diseases. It is an emerging peer on gene-therapy platform technology rather than indication overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/engene_inc
• YouTubeyoutube.com/@enGene_Inc
• LinkedInlinkedin.com/company/engene

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds11 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about enGene